RCELAVITA Medical, Inc.
Is it safe?
Caution warranted: heavy debt (CCC) and big price swings.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -94% · now at/near its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can RCEL take a bad year?
The deepest fall in RCEL's price history on file is −94%; it is 0.00% below its high today.
Net debt · as at Q2 2026 · debt less the cash on hand, with no positive EBITDA to service it
- Cash runway
- 0.4 years
Cash runway · burning $6.5M a quarter at the current rate
- Annualised volatility
- 97%
Annualised volatility · three times the market's own swing
- Worst drawdown on file
- −94%
Worst drawdown on file · 0.00% today
Details›
- Total debtQ2 2026
- $47M
- Cash and short-term investments
- $11M
- Net debt
- $36M
- EBITDA, trailing twelve months
- −$33M
- Operating profit, trailing twelve months
- −$35M
- Annualised volatilitytwo years of daily moves
- 97%
- Worst drawdown on file
- −94%
- Below its 52-week high
- 0.00%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Medical Devices
Ranks #42 of 51 by RyuScore